Holen Sie sich die Stockscreener-App
18.19
0.33%
0.06
Handel nachbörslich:
18.19
Schlusskurs vom Vortag:
$18.13
Offen:
$18.15
24-Stunden-Volumen:
826.20K
Relative Volume:
0.92
Marktkapitalisierung:
$1.04B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-100.44M
KGV:
-8.1937
EPS:
-2.22
Netto-Cashflow:
$-105.32M
1W Leistung:
-5.41%
1M Leistung:
-16.29%
6M Leistung:
-34.90%
1J Leistung:
-50.29%
1-Tages-Spanne:
$17.76
$18.50
1-Wochen-Bereich:
$17.76
$20.25
52-Wochen-Spanne:
$13.22
$45.37
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(628) 229-9277
Adresse
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Vergleichen Sie GPCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
18.19 | 1.11B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Eingeleitet | Citigroup | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target - Business Wire
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS) - The Globe and Mail
H.C. Wainwright Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Principal Financial Group Inc. Has $14.24 Million Stock Holdings in Universal Display Corporation (NASDAQ:OLED) - Defense World
Principal Financial Group Inc. Decreases Stock Holdings in Shift4 Payments, Inc. (NYSE:FOUR) - Defense World
Principal Financial Group Inc. Sells 11,305 Shares of Nova Ltd. (NASDAQ:NVMI) - Defense World
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP), Amedisys (AMED) and Xoma (XOMA) - The Globe and Mail
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Rating of “Buy” from Brokerages - Defense World
Scage Future shares rise 2.16% in after-hours after extending business merger agreement deadline and establishing ADR facility. - AInvest
Structure Therapeutics Holds 2025 Annual Shareholders Meeting - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Receives “Market Outperform” Rating from JMP Securities - Defense World
Analyst Coverage Updates: June 23rd, 2025 - The Globe and Mail
Breakthrough Oral Obesity Drug Matches Injectable Results, Shows Added Benefits With Wegovy in Trial Data - Stock Titan
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Data-Based Insights About Structure Therapeutics Inc ADR (GPCR) - Stocksregister
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Cantor Fitzgerald Comments on GPCR FY2026 Earnings - Defense World
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarketsNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
Cantor Fitzgerald Estimates GPCR FY2025 Earnings - Defense World
Oral Proteins and Peptides Market Report Latest Trends and Future Opportunities Analysis - openPR.com
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating - TipRanks
Bank of America Corp DE Has $1.47 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Viking Therapeutics at Jefferies Conference: Promising Weight Loss Drug - Investing.com
GLP-1 Receptor Agonists: The Surge of M&A Activity and the Future of Metabolic Health - The National Law Review
Structure Therapeutics Set for Jefferies and Goldman Sachs Healthcare Conference Presentations in June - Stock Titan
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - standard-journal.com
BNP Paribas Financial Markets Increases Stake in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
BNP Paribas Financial Markets Makes New $304,000 Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Bucking Biotech's Downward Trend, Circle Pharma Heads To Larger Space - Bisnow
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail
Structure Therapeutics’ SWOT analysis: oral obesity drug stock poised for growth - Investing.com
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $78.00 - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Structure Therapeutics (NASDAQ:GPCR) Price Target Lowered to $75.00 at HC Wainwright - Defense World
FY2025 Earnings Forecast for GPCR Issued By Leerink Partnrs - Defense World
Envestnet Asset Management Inc. Has $201,000 Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Tower Research Capital LLC TRC Acquires 3,549 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - The AM Reporter
Structure Therapeutics Reports Increased Losses Amid Rising R&D Costs - TipRanks
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights - Stock Titan
Wells Fargo & Company MN Boosts Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Analyzing Ratios: Structure Therapeutics Inc ADR (GPCR)’s Financial Story Unveiled - DWinneX
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), AnaptysBio (ANAB) and Alignment Healthcare (ALHC) - The Globe and Mail
Structure Therapeutics Inc ADR (NASDAQ: GPCR) Is Up 1.57% So Far This Year: What Will Happen Next? - Stocksregister
Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at Citigroup - Defense World
Structure Therapeutics Inc ADR (GPCR) expanding its growth trajectory ahead - Sete News
Buy Recommendation for Structure Therapeutics: Promising Pipeline and Obesity Treatment Market Potential - TipRanks
Citi sets Structure Therapeutics stock Buy rating, $60 target By Investing.com - Investing.com India
Technical analysis of Stoke Therapeutics Inc (STOK) stock chart patterns - uspostnews.com
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):